Claes Glassell has been appointed chief executive officer of CMC Biologics. Mr. Glassell joins the company from Cerus Corp., where he served as chief executive officer. Prior to that he was president of Cambrex Corp. Mr. Glassell joined the CMC board of directors in 2005. Previously, he held senior positions with Akzo Nobel NV, Nobel Industries AB and Berol Kemi AB. His areas of expertise include 20 years of executive positions in publicly listed life sciences companies responsible for bioprocessing, active ingredients, registered therapeutic agents and various support services.

“We are thrilled that Claes has joined the CMC executive team,” said David Kauffmann, CMC’s chairman and managing director of European Equity Partners. “Claes has been on CMC’s board of directors for more than five years, and has during that time exhibited a broad range of experience and insight of our industry. Claes’ strong leadership qualities and seasoned business understanding makes him the ideal leader to take CMC Biologics to the next level as a leader in our fast-moving industry.”